Amylin: The Next Peptide Hormone Target for Obesity Drugs After GLP-1
Amylin receptor agonists are emerging as the next wave of peptide-based obesity drugs, with combination therapies (amylin + GLP-1) showing superior weight loss to monotherapy and potentially fewer GI side effects than GLP-1 drugs alone.
Quick Facts
What This Study Found
The review identifies several key developments in amylin receptor agonist research:
• Amylin receptors are heterodimers of the calcitonin receptor and receptor activity-modifying proteins (RAMPs) — a unique and druggable receptor architecture
• Multiple amylin analogs are in preclinical and clinical development for obesity
• Combination therapy (amylin analog + other anti-obesity peptide drugs) has demonstrated higher clinical efficacy in reducing body weight than monotherapy
• Combination therapy is likely to be the first clinical application where an amylin analog is used for obesity
• Amylin receptor activators may have a more favorable adverse effect profile than GLP-1 receptor agonists
• Key engineering advances: mutations enhancing receptor affinity/potency, lipidation for long-acting properties, and methods for measuring selective amylin receptor activation
Key Numbers
How They Did This
Narrative review collecting recent research publications and drug development information on amylin receptor activators. Covers preclinical studies, clinical trials, receptor pharmacology, peptide engineering approaches, and combination therapy data.
Why This Research Matters
GLP-1 drugs dominate the obesity market, but their GI side effects limit tolerability for many patients. Amylin agonists represent a genuinely different peptide mechanism — working through the calcitonin receptor/RAMP system rather than the GLP-1 receptor. If amylin drugs prove more tolerable, they could become preferred options or powerful combination partners. The finding that amylin + GLP-1 beats either alone suggests the future of obesity pharmacotherapy may involve multi-peptide cocktails.
The Bigger Picture
The obesity drug revolution started with GLP-1 agonists, expanded to dual GIP/GLP-1 agonists (tirzepatide), and is now reaching triple agonists and amylin analogs. Amylin represents a parallel peptide pathway that complements rather than duplicates GLP-1 signaling. The trend toward multi-target peptide combinations — hitting GLP-1, GIP, glucagon, and now amylin receptors — reflects a growing understanding that obesity is driven by multiple redundant appetite pathways, and no single target may be sufficient for maximal weight loss.
What This Study Doesn't Tell Us
Narrative review without systematic methodology. Most amylin analog clinical data are from ongoing or recently completed trials with limited published details. The claim of fewer GI side effects versus GLP-1 drugs needs confirmation in head-to-head trials. Long-term safety data for amylin analogs in obesity are not available. The complexity of amylin receptor pharmacology (multiple RAMP subtypes) may complicate drug development.
Questions This Raises
- ?Will amylin-GLP-1 combination therapy become a standard treatment for obesity, and what are the optimal doses?
- ?Can amylin analogs achieve meaningful weight loss as monotherapy, or will they only be used in combinations?
- ?Which RAMP subtype-selective amylin agonists would be most effective for appetite suppression with fewest side effects?
Trust & Context
- Key Stat:
- Combination > monotherapy Amylin analog combined with other anti-obesity peptide drugs produced greater weight loss than either alone, and amylin drugs may cause fewer GI side effects than GLP-1 agonists
- Evidence Grade:
- This is a narrative review of the amylin receptor agonist field, covering preclinical through clinical-stage development. While it provides a comprehensive overview, the evidence for most claims is from early-stage clinical trials and preclinical data. The comparative advantage over GLP-1 drugs requires head-to-head clinical confirmation.
- Study Age:
- Published in 2025, this review captures the amylin drug pipeline at a pivotal moment as several candidates advance through clinical trials. The field is moving rapidly and new data may emerge soon.
- Original Title:
- A Review of Amylin Peptide Receptor Activators for Obesity Pharmacotherapy.
- Published In:
- Current drug targets, 26(14), 980-991 (2025)
- Authors:
- Lee, Sangmin(4)
- Database ID:
- RPEP-12024
Evidence Hierarchy
Frequently Asked Questions
What is amylin and how is it different from GLP-1?
Amylin is a 37-amino acid peptide hormone released from the same pancreatic cells that produce insulin, but it works through a completely different receptor system — the calcitonin receptor paired with accessory proteins called RAMPs. Like GLP-1, amylin suppresses appetite and helps control blood sugar, but through different brain pathways. This makes amylin and GLP-1 drugs complementary — they can be combined for greater weight loss than either alone.
Could amylin drugs replace GLP-1 drugs for weight loss?
They're more likely to complement them than replace them. The most exciting finding is that combining amylin with GLP-1 drugs produces better weight loss than either alone. This combination approach is expected to be the first clinical use of amylin analogs for obesity. Amylin drugs may also have fewer stomach side effects than GLP-1 drugs, making them attractive for patients who can't tolerate GLP-1 therapy on its own.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-12024APA
Lee, Sangmin. (2025). A Review of Amylin Peptide Receptor Activators for Obesity Pharmacotherapy.. Current drug targets, 26(14), 980-991. https://doi.org/10.2174/0113894501398624250819070004
MLA
Lee, Sangmin. "A Review of Amylin Peptide Receptor Activators for Obesity Pharmacotherapy.." Current drug targets, 2025. https://doi.org/10.2174/0113894501398624250819070004
RethinkPeptides
RethinkPeptides Research Database. "A Review of Amylin Peptide Receptor Activators for Obesity P..." RPEP-12024. Retrieved from https://rethinkpeptides.com/research/lee-2025-a-review-of-amylin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.